专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2002083058A3 ANTI-INFLAMMATORY FATTY ALCOHOLS AND FATTY ACID ESTERS USEFUL AS ANTIGEN CARRIERS 审中-公开
公开(公告)号：WO2002083058A3
公开(公告)日：2002-10-24
申请号：PCT/IL2002/000295
申请日：2002-04-11
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. , COHEN, Irun, R. , SHINITZKY, Meir , MARGALIT, Raanan
发明人： COHEN, Irun, R. , SHINITZKY, Meir , MARGALIT, Raanan
IPC分类号： A61K31/23
摘要： Therapeutic preparations are provided for treatment of a T-cell mediated disease or condition comprising an antigen and a carrier, wherein said antigen is an antigen recognized by inflammatory T cells associated with the pathogenesis of said T-cell mediated disease or condition, and wherein said carrier is an anti-inflammatory immunomodulator selected from: (a) a saturated or cis-unsaturated C 10 -C 20 fatty alcohol or an ester thereof with a C 1 -C 6 alkanoic acid; and (b) a saturated or cis-unsaturated C 10 -C 20 fatty acid ester selected from a C 1 -C 6 alkyl ester, a monoester with a C 2 -C 6 polyol having a least two hydroxy groups, and a diester with glycerol.

12. 发明申请

WO0149161A3 METHOD AND SYSTEM FOR MONITORING PANCREATIC PATHOLOGIES 审中-公开
标题翻译：监测胰腺病理学的方法和系统
公开(公告)号：WO0149161A3
公开(公告)日：2002-03-07
申请号：PCT/IL0100015
申请日：2001-01-07
申请人： YEDA RES & DEV , COHEN IRUN R , DEGANI HADASSA , BRUKER LIOR , MARGALIT RAANAN
发明人： COHEN IRUN R , DEGANI HADASSA , BRUKER LIOR , MARGALIT RAANAN
IPC分类号： A61B5/055 , G01R33/28 , G01R33/48 , G01R33/56
CPC分类号： G01R33/5601 , A61B5/055 , A61B5/416 , A61B5/425
摘要： A method for non invasively detecting and monitoring pancreatic pathologies preferably related to vascular changes or inflammatory processes in the pancreas, such as the onset of IDDM, by magnetic resonance imaging (MRI) is disclosed. The method enables the detection of IDDM prior to the appearance of clinical manifestation, by detecting early stages of IDDM such as insulitis. The disclosed method also enables correlation of different stages of pancreatic diseases with the characteristics of contrast enhancement curves. A MRI system for monitoring pancreatic pathology in a patient is also disclosed. the system comprises a single volume coil for transmitting and receiving signals from an internal body organ of a patient, such as the pancreas, or the spleen.
摘要翻译：公开了一种非侵入性检测和监测胰腺病理学的方法，其优选与胰腺中的血管变化或炎症过程相关，例如通过磁共振成像（MRI）的IDDM的发作。该方法能够通过检测IDDM的早期阶段（例如胰岛炎）在出现临床表现之前检测IDDM。所公开的方法还使得胰腺疾病的不同阶段与对比度增强曲线的特征相关。还公开了一种用于监测患者胰腺病理学的MRI系统。该系统包括用于从诸如胰脏或脾脏的患者的内部身体器官发送和接收信号的单个体积线圈。

13. 发明申请

WO2012160563A3 USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME 审中-公开
标题翻译：作为生物标记用于预防神经损伤性疾病和治疗的AKT磷酸化的使用
公开(公告)号：WO2012160563A3
公开(公告)日：2014-05-08
申请号：PCT/IL2012050185
申请日：2012-05-23
申请人： YEDA RES & DEV , UNIVERSITÄTSKLINIKUM HAMBURG EPPENDORF , OVADIA ERAN , COHEN IRUN R , HERKEL JOHANNES , MARGALIT RAANAN , PEVSNER-FISCHER MEIRAV
发明人： OVADIA ERAN , COHEN IRUN R , HERKEL JOHANNES , MARGALIT RAANAN , PEVSNER-FISCHER MEIRAV
IPC分类号： A61K39/00
CPC分类号： G01N33/6854 , A61K31/343 , A61K38/08 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/185 , A61K38/1866 , A61K38/1891 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/54306 , G01N33/6896 , G01N2800/28 , G01N2800/52 , A61K2300/00
摘要： The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
摘要翻译：本发明涉及包含选自SEQ ID NO：1，SEQ ID NO：2，其类似物和衍生物的氨基酸序列的肽用于治疗神经变性疾病如肌萎缩性侧索硬化（ ALS）。本发明还提供了评估对本发明的肽的治疗反应性的方法。此外，本发明涉及使用Akt和磷酸化Akt作为生物标志物的ALS进展的预后。

14. 发明申请

WO2012160563A2 USE OF AKT PHOSPHORYLATION AS A BIOMARKER FOR PROGNOSING NEURODEGENERATIVE DISEASES AND TREATING SAME 审中-公开
标题翻译：作为生物标记用于预防神经损伤性疾病和治疗的AKT磷酸化的使用
公开(公告)号：WO2012160563A2
公开(公告)日：2012-11-29
申请号：PCT/IL2012/050185
申请日：2012-05-23
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. , OVADIA, Eran , COHEN, Irun R. , HERKEL, Johannes , MARGALIT, Raanan , PEVSNER-FISCHER, Meirav
发明人： OVADIA, Eran , COHEN, Irun R. , HERKEL, Johannes , MARGALIT, Raanan , PEVSNER-FISCHER, Meirav
IPC分类号： G01N33/53 , A61K38/17
CPC分类号： G01N33/6854 , A61K31/343 , A61K38/08 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/185 , A61K38/1866 , A61K38/1891 , A61K38/30 , A61K45/06 , C07K7/06 , G01N33/54306 , G01N33/6896 , G01N2800/28 , G01N2800/52 , A61K2300/00
摘要： The present invention relates to uses of a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, analogues and derivatives thereof, for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS). The present invention further provides a method for assessing responsiveness to treatment with the peptide of the invention. In addition, the present invention relates to prognosis of ALS progression, using Akt and phosphorylated Akt as biomarkers.
摘要翻译：本发明涉及包含选自SEQ ID NO：1，SEQ ID NO：2，其类似物和衍生物的氨基酸序列的肽用于治疗神经变性疾病如肌萎缩性侧索硬化（ ALS）。本发明还提供了评估对本发明的肽的治疗反应性的方法。此外，本发明涉及使用Akt和磷酸化Akt作为生物标志物的ALS进展的预后。

15. 发明申请

WO2003047501A2 NOVEL ANTI-CANCER THERAPEUTIC COMPOUNDS 审中-公开
标题翻译：新型抗癌治疗化合物
公开(公告)号：WO2003047501A2
公开(公告)日：2003-06-12
申请号：PCT/IL2002/000982
申请日：2002-12-05
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. , CAHALON, Liora , COHEN, Irun, R. , LIDER, Ofer , MARGALIT, Raanan
发明人： CAHALON, Liora , COHEN, Irun, R. , LIDER, Ofer , MARGALIT, Raanan
IPC分类号： A61K
CPC分类号： C07H5/06 , A61K31/7012 , A61K31/7016 , A61K31/702 , A61K31/7024 , A61K31/727 , A61K31/737
摘要： A treatment for cancer, and in particular, of therapeutic compounds which block the ability of cytokines and chemokines to promote metastasis of malignant cells. The therapeutic compound comprises a carboxylated and/or sulfated oligosaccharide, preferably in a substantially purified form, which is a heparin or heparan-sulfate derived saccharide compound. In one embodiment of the present invention, the carbohydrate or oligosaccharide has a molecular weight of no more than about 3000 daltons, preferably lying in the range of about 400 to about 2000 daltons, most preferably between about 400 and about 1100 daltons. Generally, substances of the present invention inhibit tumor cell migration, as determined by biological assays, and comprise molecules of various sugar units of which the basic unit of activity is associated with a disaccharide. However, larger oligosaccharide chains of up to about 10 sugar units, containing the basic disaccharide unit of activity can also function to inhibit such activity.
摘要翻译：癌症治疗，特别是阻断细胞因子和趋化因子促进恶性细胞转移的能力的治疗化合物。治疗化合物包含羧化和/或硫酸化的寡糖，优选基本上纯化的形式，其是肝素或硫酸乙酰肝素衍生的糖类化合物。在本发明的一个实施方案中，碳水化合物或寡糖的分子量不超过约3000道尔顿，优选在约400至约2000道尔顿范围内，最优选约400至约1100道尔顿。通常，本发明的物质通过生物测定法测定，抑制肿瘤细胞迁移，并且包含其基本活性单位与二糖相关的各种糖单元的分子。然而，含有活性的碱性二糖单位的高达约10个糖单元的较大的寡糖链也可以起到抑制这种活性的作用。

16. 发明申请

WO2002083058A2 ANTI-INFLAMMATORY FATTY ALCOHOLS AND FATTY ACID ESTERS USEFUL AS ANTIGEN CARRIERS 审中-公开
标题翻译：抗炎药物和脂肪酸作为抗原携带者有用
公开(公告)号：WO2002083058A2
公开(公告)日：2002-10-24
申请号：PCT/IL2002/000295
申请日：2002-04-11
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. , COHEN, Irun, R. , SHINITZKY, Meir , MARGALIT, Raanan
发明人： COHEN, Irun, R. , SHINITZKY, Meir , MARGALIT, Raanan
IPC分类号： A61K
CPC分类号： A61K39/385 , A61K47/54 , A61K47/542 , A61K47/543 , A61K2039/60
摘要： Therapeutic preparations are provided for treatment of a T-cell mediated disease or condition comprising an antigen and a carrier, wherein said antigen is an antigen recognized by inflammatory T cells associated with the pathogenesis of said T-cell mediated disease or condition, and wherein said carrier is an anti-inflammatory immunomodulator selected from: (a) a saturated or cis-unsaturated C 10 -C 20 fatty alcohol or an ester thereof with a C 1 -C 6 alkanoic acid; and (b) a saturated or cis-unsaturated C 10 -C 20 fatty acid ester selected from a C 1 -C 6 alkyl ester, a monoester with a C 2 -C 6 polyol having a least two hydroxy groups, and a diester with glycerol.
摘要翻译：提供治疗性制剂用于治疗包含抗原和载体的T细胞介导的疾病或病症，其中所述抗原是由与所述T细胞介导的疾病或病症的发病机制相关的炎性T细胞识别的抗原，其中所述载体是选自以下的抗炎免疫调节剂：（a）饱和或顺式不饱和的C 10 -C 20脂肪醇或其具有C 1 -C 6链烷酸的酯; 和（b）饱和或顺式不饱和的C 10 -C 20脂肪酸酯，其选自C 1 -C 6烷基酯，C 2 -C 6的单酯，具有至少两个羟基的多元醇和具有甘油的二酯。

17. 发明申请

WO1994011006A1 COMPOSITIONS FOR THE REGULATION OF CYTOKINE ACTIVITY 审中-公开
标题翻译：用于调节细胞因子活性的组合物
公开(公告)号：WO1994011006A1
公开(公告)日：1994-05-26
申请号：PCT/US1993010868
申请日：1993-11-09
申请人： YEDA RESEARCH AND DEVELOPMENT CO. LTD. , COHEN, Irun, R. , LIDER, Ofer , CAHALON, Liora , SHOSEYOV, Oded , MARGALIT, Raanan
发明人： YEDA RESEARCH AND DEVELOPMENT CO. LTD.
IPC分类号： A61K31/725
CPC分类号： A61K31/7024 , A61K31/70 , A61K31/7016 , C07H11/00
摘要： Substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, including compositions containing same and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of Tumor Necrosis Factor Alpha (TNF- alpha ) can be either inhibited or augmented selectively by administration to the host of effective amounts of substances or their compositions comprising specific oligosaccharides in substantially purified form. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the induction of active cytokine secretion, such as TNF- alpha . The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of up to about 5-8 days, preferably once a week.
摘要翻译：包括基本上纯化形式的羧化和/或硫酸化寡糖的物质，包括含有它们的组合物和使用它们的方法被公开用于调节宿主中的细胞因子活性。例如，肿瘤坏死因子α（TNF-α）的分泌可以通过向宿主施用有效量的物质或其包含基本纯化形式的特异性寡糖的组合物来选择性地被抑制或增强。因此，本发明还涉及药物组合物及其用于预防和/或治疗涉及诱导活性细胞因子分泌的病理过程如TNF-α的用途。本发明还涉及由宿主引起包括病原体在内的活化剂的存在引起所需的免疫系统相关应答。本发明的物质和药物组合物可以是非常低的有效剂量，通常低于0.1mg / kg人，或间隔至多约5-8天，优选每周一次。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式